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Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) constitute serious public health problems 
worldwide. In Sierra Leone, information on both viral infections remains scanty. This study estimated the 
seroprevalence of HIV and HBV infections and a possible co-infection in one hundred and ninety-eight (198) 
patients seeking diagnosis at a private laboratory in Freetown, Sierra Leone. Blood plasma was collected 
from each patient after informed consent was obtained. The samples were assayed for antibodies to HIV 
virus and HBV antigen using appropriate assays. Male patient accounts for 52% of the population examined. 
Thirty-one (31) of the 198 patients examined (15.7%) were positive for HIV. Hepatitis B surface antigen 
(HbsAg) was present in 17 (39.5%) females and 26 (60.5%) males. Thirteen (13) (6.6%) patients were co-
infected with HIV and HBsAg. This is the first documented evidence of HBsAg and HIV co-infection in Sierra 
Leoneans. Larger population based studies are however needed to confirm the findings. 
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INTRODUCTION 
Human immunodeficiency virus and hepatitis B 
virus are among the leading causes of morbidity 
and mortality. Human Immunodeficiency Virus 
(HIV) is a retrovirus having two strains:  HIV 1 and 
2. The virus belongs to a group of cytopathic 
lentiviruses.  On the other hand, Hepatitis B virus 
(HBV) is a double-stranded, enveloped DNA virus 
belonging to the Hepadnaviridae family. The core 
antigen (HBcAg), envelope antigen (HBeAg) and 
surface antigen (HBsAg) are most important HBV 
antigens and markers (Eugene et al., 2004).  
However, HBsAg remains the main marker of 
HBV disease and appears shortly after acute 
infection (Brito and Alhyraba, 2008).  Both HIV 
and HBV are known to be transmitted through 
sexual intercourse, blood and blood products, 
shared needle, other body fluids such as vaginal 
fluid, semen and breast milk (Koziel and Peters, 
2007).  Because of the overlap in risk factors, it is 
therefore common for some patients to be 
infected with both viruses. HIV/HBV co-infection is 
associated with increased risks of liver-related 
diseases including hepatocellular carcinoma 
(Benhamou, 2004).  
 
The estimated prevalence of chronic hepatitis B 
virus (HBV) infection in patients with HIV infection 
is between 7.6% and 11% in the United States 
(Brito and Alhyraba, 2008). In sub- Sahara Africa , 
for instance, Ghana, HIV seroprevalence of HIV is 
between 3.8-19.2% (Ampofo et al., 2002; Adjei et 
al., 2006) and HBsAg was detected among 30 of 
70 cases of liver cirrhosis, giving a prevalence 
rate of 42.9% compared to 7.5% (21 out of 280) 
among the negative population (Blankson et al., 
2005).
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Studies on the prevalence of HIV and HBV co-
infection among Sierra Leoneans have not be 
done but, there are speculations that the 
prevalent rate of both infections in Sierra Leone 
might be among the lowest in sub-Saharan Africa.  
The Sierra Leone NAS and some workers 
estimate HIV prevalence at 0.9 - 3.29% (Sierra 
Leone NAS, 2006; Sahr et al., 2008). Other 
independent studies estimate HBV prevalent at 
2.6%- 5.1% (Wurie et al., 1995; Garcı´a-Calleja et 
al., 2006).  
 
We studied the prevalence of HIV and HBV using 
the surface antigen marker in patients seeking 
diagnosis services at a private health facility in 
Freetown Sierra Leone. All the patients were 
unhospitalised, had no prior knowledge of their 
HIV or HBV status and chosen not only because 
previous studies have targeted selected groups to 
determine the national prevalence of either of the 
infection but to reflect possible mis-diagnosis of 
either of the viral infection. The prevalence of co-
infection with the two viruses among the patients 
was also examined.    
 
MATERIALS AND METHODS 
Setting/Study Population 
This study is a cross-sectional study conducted 
over a two months period at a private diagnostic 
centre in downtown Freetown, Sierra Leone. The 
diagnostic centre is a well equipped, reputable 
clinical laboratory, with its clientele from all over 
the country. As a result, the centre presents an 
integral part of health services for survey of 
diseases in Sierra Leone. All persons referred to 
the laboratory from different hospitals for either 
Hepatitis B or HIV testing based on suspicion on 
clinical ground were investigated during the study 
period. Those requesting for HIV testing were 
tested for HBV alongside the required test and 
those requesting for HBsAg were tested for HIV. 
Some of the patients chose not to disclose their 
age but all, confirmed they were above eighteen 
years of age. The patients were counseled and 
informed consent was obtained after the study 
was fully explained to them. They were assured 
the confidentiality of the results of the study.  
 
Sample Collection and Analysis 
10mls of venous blood was aseptically collected 
from each of the participants using plasma 
specimen EDTA collection tubes. The Plasma 
were kept up to three days at 2-8
o
C. Strategy III 
recommendation of the Joint United Nations 
Program on HIV/AIDS and WHO which involves 
three rapid assays for diagnosis and surveillance 
in low prevalent countries (UNAIDS, 1997) was 
employed for HIV testing.  As instructed by each 
kit manufacturer, all the plasma samples were 
tested for the presence of HIV antibodies with the 
Abbot determine HIV 1 & II, trinity Biotech’s 
Capillus HIV 1/HIV 2, and Uni-Gold (Trinity 
Biotech, Ireland). Only samples with positive 
reactions with the three kits were considered 
positive. Hepatitis B infection status was tested 
with HBsAg latex (Abbott, USA), a slide 
agglutination test, and the manufacturer’s 
procedures and recommendations were followed. 
Latex particles coated with monoclonal antibodies 
anti-HBsAg are agglutinated when mixed with 
samples containing HBsAg. A homogenous 
suspension of the latex particles and the sample 
indicates negative result. 
 
Data Analysis 
Data were recorded on a structured compilation 
sheet using SPSS version 12.0.  
 
RESULTS AND DISCUSSION  
In this study, 198 patients were examined for HIV 
and HBV infections. Seroprevalence assessment 
of HIV provides essential information for 
instituting and implementation of AIDS control 
programs and for monitoring HIV transmission 
within a country.  15.7% (31 of 198) were infected 
with HIV (Table 1). This is significantly higher than 
that of the national HIV/AIDS estimate of 2.1% in 
urban setting in Sierra Leone (Garcı´a-Calleja et 
al., 2006). Nonetheless the prevalence is 
consistent with the reported prevalent rate in a 
hospital based study carried out in Tansen Palpa, 
Nepal among clinically suspected cases (Napit, 
2001).  
 
The HBsAg seroprevalence among the cohort 
studies was found to be 21.7% (43 out 0f 198) 
(Table 1). Of these hepatitis B virus mono-
infected patients, seroprevalence of hepatitis B 
among males and females was 25.5% and 17.7% 
respectively. This high percentage of HBsAg in 
males correlates with the number of subjects 
screened and the results corroborate that of 
Muktar and co-workers which shows that none of 
the six females examined in their study tested 
positive for Hepatitis B surface antigen (Muktar et 
al., 2005). The prevalence of hepatitis B infection 
varies from country to country and depends upon 
a complex mix of host, behavioural and 
environmental factors. It has been documented to 
be highest in regions with low socioeconomic 
levels. 
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In Sierra Leone, previous studies have reported 
5.1% among middle to high socio-economic 
antenatal population (Wurie et al., 1995) and 
2.6% in a population of primary school children in 
Freetown, Sierra Leone (Hodges et al., 1998). 
One possible explanation for these discrepancies 
could be the differences in the sensitivity and 
specificity of the latex agglutination technique 
employed for HbsAg screening. Additionally, the 
high percentage could be attributed to differences 
in socio-demographic background our study 
cohort and those of other studies. Thus, we 
probably overestimate the true prevalence among 
the cohort examined. Figure 1 summaries the 
disease burden of the infections among the 
cohort. It would therefore be interesting to 
investigate the impact of selected socio-
demographic variables in the transmission of this 
infection in subsequent studies. Nevertheless, 
based on the latex agglutination method, the over 
20% HBsAg seroprevalence reported in this study 
is similar to reports from other developing 
countries (Alao et al., 2009).  
 












Figure 1: Summary of the Disease Burden 
among the 198 Patients 
 
Results of this current study also revealed that 
6.6% (13 out of 198) of the patients were co-
infected with HIV and HBsAg. Co-infection with 
human immunodeficiency virus (HIV) and 
hepatitis B virus (HBV) has become a major 
global problem, leading to increased morbidity 
and mortality in developing countries. This 
however is the first report on the co-infection of 
HIV and HBV in Sierra Leone and it is particularly 
worrisome since it may pose a significant burden 
to health care services. Patients co-infected with 
HIV and HBV are known to have high progression 
to hepatitis fibrosis and other complications than 
those with HIV or HBV mono-infection (Brito and 
Alhyraba, 2008). 
 
Considering the overall prevalence, it is intricate 
to compare our findings with other studies that are 
population based. However, this observed 
prevalence for the two viral infections may not be 
unanticipated since the subjects were already 
clinically suspected of having either HIV or HBV 
infections at a single health facility. This clearly 
increases case detection and may unlikely be 
representative of the general Sierra Leonean 
populace. The absence of data regarding risk 
factors and the ages of the patients also present a 
drawback. Regardless of these limitations, we 
consider that this study contains valuable 
information on the emerging trend of these viral 
infections in Sierra Leone. Also, we are of the 
opinion that either or both infections may be on 
the increase. 
 
In conclusion, findings from this study have raised 
pertinent issues of public health importance 
particularly the co-infection of both viruses among 
patients in Freetown, Sierra Leone. In order to 
clearly define the disease burden, assess the 
transmission routes and other risk factors, there is 
a need to undertake a properly designed 
population study involving various populations so 
that proper public health measures could be 
instituted. Health education services and support 
programs for HIV/AIDS and HBV such as 













No (%)  
with  
HBsAg 
No (%)  Co-
infected 
with HIV1/2 
+  HBsAg 
Male 102 17(54.8) 26 (60.5) 6(46.2) 
Female 96 14(45.2) 17 (39.5) 7(53.8) 
Total 198 31 43 13 
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